https://www.biospace.com/employer/3076371/serb-pharmaceuticals SERB Pharmaceuticals en-US Tue, 02 Mar 2021 07:06:14 GMT https://www.biospace.com/serb-completes-acquisition-of-btg-specialty-pharmaceuticals-to-create-a-global-leader-in-critical-care-medicines SERB Specialty Pharmaceuticals, a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases, announced the acquisition of BTG Specialty Pharmaceuticals, a division of Boston Scientific that develops, manufactures, and commercializes antidotes and rescue medicines to treat patients with critical conditions. Tue, 02 Mar 2021 07:06:14 GMT https://www.biospace.com/serb-completes-acquisition-of-btg-specialty-pharmaceuticals-to-create-a-global-leader-in-critical-care-medicines https://www.biospace.com/thomas-kolaras-joins-serb-and-btg-specialty-pharmaceuticals-as-us-chief-commercial-officer SERB and BTG Specialty Pharmaceuticals are pleased to announce that Thomas Kolaras has been named the group’s new Chief Commercial Officer for its US business. Mon, 11 Apr 2022 11:16:07 GMT https://www.biospace.com/thomas-kolaras-joins-serb-and-btg-specialty-pharmaceuticals-as-us-chief-commercial-officer https://www.biospace.com/soligenix-announces-strategic-partnership-with-serb-pharmaceuticals-to-supply-its-novel-ricin-antigen Soligenix, Inc. announced today that it has signed a worldwide exclusive license to supply its ricin antigen to SERB Pharmaceuticals (SERB), for development of a novel therapeutic treatment against ricin toxin poisoning. Mon, 25 Jul 2022 11:36:09 GMT https://www.biospace.com/soligenix-announces-strategic-partnership-with-serb-pharmaceuticals-to-supply-its-novel-ricin-antigen https://www.biospace.com/serb-pharmaceuticals-and-sfj-pharmaceuticals-announce-a-u-s-partnership-for-bentracimab-a-ticagrelor-reversal-agent SERB Pharmaceuticals announce that SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ. Bentracimab is a novel, monoclonal antibody fragment designed to reverse the antiplatelet activity of ticagrelor. Thu, 11 May 2023 11:36:12 GMT https://www.biospace.com/serb-pharmaceuticals-and-sfj-pharmaceuticals-announce-a-u-s-partnership-for-bentracimab-a-ticagrelor-reversal-agent https://www.biospace.com/serb-pharmaceuticals-acquires-vistogard-and-xuriden-from-wellstat-therapeutics SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard ® (uridine triacetate) and Xuriden ® (uridine triacetate), from Wellstat Therapeutics. Thu, 13 Jul 2023 12:06:16 GMT https://www.biospace.com/serb-pharmaceuticals-acquires-vistogard-and-xuriden-from-wellstat-therapeutics https://www.biospace.com/serb-pharmaceuticals-grants-exclusive-license-to-m8-pharmaceuticals-an-acino-company-to-bring-voraxaze-glucarpidase-to-cancer-patients-in-latin-america SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company (“M8”) are collaborating to bring an important drug for cancer patients to Latin America. Wed, 20 Mar 2024 13:06:04 GMT https://www.biospace.com/serb-pharmaceuticals-grants-exclusive-license-to-m8-pharmaceuticals-an-acino-company-to-bring-voraxaze-glucarpidase-to-cancer-patients-in-latin-america https://www.biospace.com/eusa-pharma-announces-sale-of-critical-care-business-to-serb-pharmaceuticals Completes EUSA's transition into oncology and rare disease-focused biopharmaceutical company Wed, 11 Jul 2018 08:06:08 GMT https://www.biospace.com/eusa-pharma-announces-sale-of-critical-care-business-to-serb-pharmaceuticals https://www.biospace.com/serb-pharmaceuticals-appoints-vanessa-wolfeler-as-ceo-to-drive-next-stage-of-the-company-s-growth SERB Pharmaceuticals has appointed Vanessa Wolfeler as its new Chief Executive Officer (CEO) effective 3 June 2024. Thu, 30 May 2024 11:06:12 GMT https://www.biospace.com/serb-pharmaceuticals-appoints-vanessa-wolfeler-as-ceo-to-drive-next-stage-of-the-company-s-growth https://www.biospace.com/emergent-biosolutions-completes-sale-of-rsdl-reactive-skin-decontamination-lotion-kit-to-serb-pharmaceuticals-for-75-million Wed, 31 Jul 2024 13:14:41 GMT https://www.biospace.com/emergent-biosolutions-completes-sale-of-rsdl-reactive-skin-decontamination-lotion-kit-to-serb-pharmaceuticals-for-75-million https://www.biospace.com/press-releases/serb-pharmaceuticals-expands-leading-emergency-care-portfolio-with-acquisition-of-aurlumyn-iloprost-iv-for-severe-frostbite Tue, 22 Oct 2024 05:04:58 GMT https://www.biospace.com/press-releases/serb-pharmaceuticals-expands-leading-emergency-care-portfolio-with-acquisition-of-aurlumyn-iloprost-iv-for-severe-frostbite